The Promise and Pitfalls of Molecular Testing in Oncology
Dr. Chris Gaj explores the challenges and potential consequences for stakeholders in the US, Europe and emerging markets in the latest issue of pharmaphorum's Deep Dive (Published June 2019).
Early targeted therapies, such as the tyrosine kinase inhibitor erlotinib from Roche/Genentech/OSI, offered the promise of precision medicine to treat cancer at a molecular level. Oncologists noted individual “Lazarus-like” responses to erlotinib, but overall effectiveness was moderate in unselected populations. It was not until the discovery that specific activating mutations in the epidermal growth factor receptor (EGFr) conveyed sensitivity to erlotinib that oncologists could identify the patients most likely to respond and target them for treatment while limiting exposure to those unlikely to respond.
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Novel cancer therapies are offering patients new treatments and better outcomes worldwide. And recent changes in healthcare policies across APAC, such as China’s fast tracking approval of therapies for severe and rare diseases, have reignited interest in the APAC region as a strong market for oncology.
Combination therapies in oncology: The benefits of integrated insights
In association with Pharmaceutical Executive
Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.
How published research underpinned a cancer therapy awareness campaign
Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment -and wanted to better understand the disease and treatment challenges faced by both patients and physicians across Asia. In addition, our client also wanted to establish KOLs to advocate for the management of OM by raising the overall disease awareness, understanding and provision of better support for the wider healthcare community. In order to achieve this our client intended to submit the research for publication in a leading medical journal.
How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy
Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests or therapies. Time constraints limited the ability for a full qualitative phase.